Figure 4: Population-averaged SHI-lag (with 95% CI) in access to health benefits from sumatriptan for the treatment of migraine attack according to age. All ages combined, the SHI system and the country as a whole lagged behind by approximately one and a half year in terms of access to sumatriptan. Reproduced from Epidemiology 2004; 15(2): 202-207. 2004, Lippincott Williams & Wilkins © .